Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 18/20 | 0.74 |
| ▸ | ITGB2 | P05107 | 16/20 | 0.74 |
| ▸ | ICAM1 | P05362 | 16/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196769 | 0.92 | ITGAL (0.74) | ITGALITGB2ICAM1PLA2G4A | |
| SCHEMBL7619878 | 0.92 | ITGAL (0.74) | ITGALITGB2ICAM1PLA2G4A | |
| SCHEMBL6197592 | 0.91 | ITGAL (0.75) | ITGALITGB2ICAM1 | |
| SCHEMBL27492375 | 0.91 | ITGAL (0.73) | ITGALITGB2ICAM1PLA2G4A | |
| SCHEMBL27474904 | 0.91 | ITGAL (0.75) | ITGALITGB2ICAM1 | |
| SCHEMBL5830300 | 0.91 | ITGAL (0.73) | ITGALITGB2ICAM1PLA2G4A | |
| SCHEMBL6198641 | 0.91 | ITGAL (0.79) | ITGALITGB2ICAM1 | |
| SCHEMBL6736459 | 0.91 | ITGAL (0.84) | ITGALITGB2ICAM1 | |
| SCHEMBL6736456 | 0.91 | ITGAL (0.84) | ITGALITGB2ICAM1 | |
| SCHEMBL28761950 | 0.91 | ITGAL (0.84) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | claimed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | claimed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | claimed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | claimed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| US-RE39197-E1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2005-11-10 | — | — | US | disclosed |
| EP-1140814-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6878700-B1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867203-B2 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1481968-A2 | Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds | Abbott Laboratories (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040116518-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| EP-1175615-A2 | LFA-1 REGULATORY BINDING SITE AND USES THEREOF | ICOS CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000060355-A2 | LFA-1 REGULATORY BINDING SITE AND USES THEREOF | ICOS CORPORATION (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6110922-A | ARYL SULFIDE CONTAINING PENDANT CIS- OR TRANS-CINNAMIDE GROUPS | ABBOTT LABORATORIES (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250768-A1 | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | ICAM1, VCAM1, EPCAM | ITGAL 57/4885ITGB2 32/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.